Nombre del producto:4-Chloro-6,7-dimethoxyquinazoline

IUPAC Name:4-chloro-6,7-dimethoxyquinazoline

CAS:13790-39-1
Fórmula molecular:C10H9ClN2O2
Pureza:98%
Número de catálogo:CM121387
Peso molecular:224.64

Unidad de embalaje Stock disponible Precio($) Cantidad
CM121387-25g in stock źǯ
CM121387-100g in stock ȎźŢ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :13790-39-1
Fórmula molecular:C10H9ClN2O2
Punto de fusión:-
Código de sonrisas:COC1=CC2=NC=NC(Cl)=C2C=C1OC
Densidad:
Número de catálogo:CM121387
Peso molecular:224.64
Punto de ebullición:345.5°C at 760 mmHg
Nº Mdl:MFCD01570172
Almacenamiento:Keep in inert atmosphere, store at 2-8°C.

Category Infos

Quinazolines
Quinazolines belong to heterocyclic chemistry, also known as 1,3-naphthalenes. The backbone consists of two six-membered aromatic rings fused to each other, with two nitrogen atoms at positions 1 and 3 on the backbone. The presence of these two nitrogen atoms in quinazoline increases its importance in pharmaceutical and biological reactions. Quinazolines and their derivatives are among the most important heterocyclic compounds due to their diverse chemical reactivity and important range of biological activities.

Column Infos

Fruquintinib
November 08, 2023, FDA has approved FRUZAQLA(fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.
FRUZAQLA is the first and only selective inhibitor of all three VEGF receptor kinases approved in the U.S. for previously treated mCRC regardless of biomarker status.

Related Products